5
Aug
2025
VIDEO: Phil Sharp and Bill Haney on ‘Cracking the Code’
Science and society have always had an uneasy relationship. Yet there are always people out there seeking to build bridges of understanding. I recently moderated a conversation at MIT with Phil Sharp, the Nobel Prize-winning biologist, and Bill Haney, a filmmaker and biotech entrepreneur with Dragonfly Therapeutics and Skyhawk Therapeutics. They collaborated on a documentary film called “Cracking the Code.”... Read More
31
Jul
2025
GSK Doubles Down on China, Sarepta Rebounds, and Frazier’s $1.3B Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2025
Sarepta Crashes, Abivax Soars, & Sanofi Buys Another Vaccine Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2025
Creative Ways to Back Young Scientists: Andy Rachleff and Yung Lie on The Long Run
Yung Lie and Andy Rachleff are today’s guests on The Long Run. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation, based in New York. Andy is the board chair. Andy was one of the founding partners of Benchmark Capital, the prominent Silicon Valley VC firm, and today is the chairman of Wealthfront. This is a... Read More
22
Jul
2025
Avalyn Pharma Gets $100M to Deliver Inhalable Pulmonary Fibrosis Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jul
2025
Omega Funds, Delivering New Products and Returns, Secures $647M New Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
5AM-Founded Renasant Bio Secures $54.5M Seed for ADPKD Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2025
A Two-Pronged Attack on Cancer: Claire Mazumdar on The Long Run
Claire Mazumdar is today’s guest on The Long Run. She is the founding CEO of Boston-based Bicara Therapeutics. Bicara is developing a bifunctional antibody for head and neck cancer. It’s called ficerafusp alfa, and it’s designed to bind with a couple of well-known biological targets, EGFR and TGF-beta. The idea is to block a well-known cancer driver in EGFR, while... Read More
25
Jun
2025
The Unsung Community Heroes Who Make Biotech Thrive
Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders. These are people who attend boring night meetings. They aren’t household names. They’re fine with that. These people were especially common in America after World War II. They laid down... Read More
18
Jun
2025
Actio Bio, Running Fast and Lean, Pockets $66M for Precision Neuro Drug R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jun
2025
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jun
2025
Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run
John Rinn is today’s guest on The Long Run. John is the Leslie Orgel and Marvin Caruthers professor of RNA science at the University of Colorado in Boulder. His research is focused on long non-coding RNAs. This is the vast expanse of the genome that doesn’t contain genes with code for making proteins. Researchers once dismissed this area of the... Read More
5
Jun
2025
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jun
2025
Request an Invitation to the Timmerman Traverse
Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy causes — including cancer research, sickle cell disease and fighting poverty. Here’s how to get involved. Timmerman Traverse for Life Science Cares This 2-day expedition... Read More
29
May
2025
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
May
2025
A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run
Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There... Read More
27
May
2025
GlycoEra Grabs $130M to Develop Extracellular Degraders for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2025
Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2025
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.